Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

4 big deal reports: Dan Loeb no longer interested in SiriusPoint

Published 14/05/2023, 16:26
Updated 14/05/2023, 16:26
© Reuters.

© Reuters.

By Davit Kirakosyan

Investing.com -- Here is your Pro Recap of the most head-turning deal dispatches you may have missed this week: disappointment at SiriusPoint, positive news for Microsoft-Activision, Shockwave Medical attracts two suitors; and Syneos Health gets bought out.

InvestingPro subscribers got this news in rapid fire. Never be left in the dust again.

Dan Loeb is no longer exploring acquisition of SiriusPoint

Siriuspoint (NYSE:SPNT) shares dropped more than 9% on Friday after Daniel Loeb declared it is no longer exploring a potential acquisition of the company, as reported in real time on InvestingPro.

This comes after a month the billionaire investor, who manages Third Point hedge fund, expressed his interest in taking SiriusPoint private. According to the regulatory filing, Loeb and the insurance firm failed to agree on the value of the deal.

EU set to approve Microsoft-Activision deal next week

EU is poised to approve Microsoft (NASDAQ:MSFT) - Activision Blizzard (NASDAQ:ATVI) deal next week, according to a report from Bloomberg on Wednesday.

This comes after the United Kingdom's Competition and Markets Authority (CMA) issued an order last month blocking the pending deal, citing concerns that the deal would harm competition in the fast-growing cloud gaming market.

InvestingPro | Prevent Losses

Shockwave Medical attracts more takeover interest

Shockwave Medical (NASDAQ:SWAV) picked up takeover interest from two additional suitors, Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT), according to InvestingPro sources.

Earlier this week, it was reported that discussions between the company and the original suitor Boston Scientific (NYSE:BSX) have ended due to a disagreement on the price.

During the company's earnings call this week, Shockwave CEO Douglas Godshall mentioned that although they do not address rumors and speculation, they would carefully consider any offer that is presented to their Board.

Syneos Health bought out for $7B

Syneos Health (NASDAQ:SYNH) shares jumped more than 8% on Wednesday following the official announcement of its acquisition by a private consortium of investment firms for $43 per share, in an all-cash deal valuing the company at around $7.1 billion.

The consortium includes Elliott Investment Management, Patient Square (NYSE:SQ) Capital, and Veritas Capital.

Get a leg up on the market: Always be the first to know with InvestingPro.

Start your free 7-day trial now.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.